Morning administration of temozolomide in glioblastoma increased OS in O6-Methylguanine-DNA-methyltransferase (MGMT) methylated patients, which was consistent with the peak expression of the clock gene BMAL1. This evidence concerns the gene BMAL1 and glioblastoma.